Gastroenterology
1 drug is in development for Nonalcoholic Steatohepatitis (NASH).
- Companies
- 1
- Clinical trials
- 8
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Nonalcoholic Steatohepatitis (NASH) pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| seladelpar | CymaBay Therapeutics, Inc. (CBAY) |
About this indication
Nonalcoholic Steatohepatitis (NASH) context
Gastroenterology·MeSH: Non-alcoholic Fatty Liver Disease (D065626)
Narrower concept of MeSH descriptor NAFLD
Prevalence
5000.0 / 100K
Incidence
500.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Nonalcoholic Steatohepatitis (NASH)?
BioSniper tracks 1 drug in development for Nonalcoholic Steatohepatitis (NASH) across 1 company.
How many clinical trials target Nonalcoholic Steatohepatitis (NASH)?
There are 8 clinical trials targeting Nonalcoholic Steatohepatitis (NASH) tracked by BioSniper.
What is the prevalence of Nonalcoholic Steatohepatitis (NASH)?
The estimated prevalence of Nonalcoholic Steatohepatitis (NASH) is approximately 5000.0 per 100,000 population.